eieio, Sigma-Aldrich bought the exclusive licence for all non-therapeutic ddRNAi some years back. So, if MIT produced MISSION shRNA using BLT's patented technology and make money selling it, presumably they would require a sub-licence from Sigma-Aldrich. They probably have a quid pro-quo type of arrangement.
BLT in turn receive royalties from Sigma-Aldrich on sub-licences they issue and royalties on sales. But, given the income over the last few years, it appears to be minimal.
- Forums
- ASX - By Stock
- mission shrna library
eieio, Sigma-Aldrich bought the exclusive licence for all...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online